Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBlencowe Resources Regulatory News (BRES)

Share Price Information for Blencowe Resources (BRES)

Share Price is delayed by 15 minutes
Get Live Data
8.10    0.06 (0.75%)
Bid:
7.90
Ask:
8.30
Spread: 0.40 (5.063%)
Market Cap: £39.85m
BRES Live PriceLast checked at - London Stock Exchange

Intraday Blencowe Resources Share Chart

DFS Performance Shares - Replacement

7 Jan 2026 09:17

RNS Number : 9854N
Blencowe Resources PLC
07 January 2026
 

7 January 2026

This is a replacement to RNS 1504N dated 30 December 2025. The date of admission has changed to 12 January 2026 and the total voting rights is now 477,295,645 following admission of the DFS Performance Shares.

 

Blencowe Resources Plc

("Blencowe" or the "Company")

 

Issue of DFS Performance Shares

 

Blencowe Resources Plc (LSE: BRES) announces that it has issued 12,000,000 DFS Performance Shares.

The DFS Performance Options have now vested following the completion and publication of the company's Definitive feasibility Study on 1 December 2025. Accordingly, the Company is now required to issue 12,000,000 new ordinary shares as set out below (the "DFS Performance Shares").

Each holder of the DFS Performance Shares has agreed to a lock up for a period of 12 months from Admission.

Director

DFS Performance shares issued

Current holdings

Holdings on Admission

Holdings % of Enlarged Share Capital

Cameron Pearce

3,000,000

13,016,667

16,016,667

3.4%

Mike Ralston

3,000,000

10,891,666

13,891,666

2.9%

Iain Wearing

3,000,000

10,461,666

13,461,666

2.8%

Lionshead Consultants Ltd *

2,250,000

7,833,334

10,083,334

2.1%

Alex Passmore

750,000

2,816,667

3,566,667

0.7%

* beneficially owned by Sam Quinn

Admission and Total Voting Rights

An application has been made for 12,000,000 Ordinary Shares to be admitted to trading on the Equity (Transition) category of the official list and the main market of the London Stock Exchange from 8.00 a.m. on 12 January 2026 ("Admission").

In accordance with the FCA's Disclosure Guidance and Transparency Rules, the Company confirms that following Admission, the Company's enlarged issued ordinary share capital will comprise 477,295,645 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury. Therefore, following Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information please contact:

 

Blencowe Resources Plc

Sam Quinn

 

www.blencoweresourcesplc.com

Tel: +44 (0)1624 681 250

info@blencoweresourcesplc.com

 

Investor Relations

Sasha Sethi

Tel: +44 (0) 7891 677 441

sasha@flowcomms.com

 

Tavira Financial 

Jonathan Evans

Tel: +44 (0)20 3192 1733

jonathan.evans@tavira.group

 

 

Twitter https://twitter.com/BlencoweRes

LinkedIn https://www.linkedin.com/company/72382491/admin/

 

 

 

 

Appendix

Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them

(This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 

1. Cameron Pearce

2. Mike Ralston

3. Iain Wearing

4. Lionshead Consultants (S Quinn)

5. Alexander Passmore

 

 

2

Reason for the notification

a)

Position/status

1. Director

2. Manager

3. Manager

4. Director

5. Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Blencowe Resources PLC

b)

LEI

 

213800UX1HBIRK36GG11

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares

 

 

 

GB00BFCMVS34

b)

Nature of the transaction

Exercise of Share options

c)

Price(s) and volume(s)

Price

Volume

1. 0.005

2. 0.005

3. 0.005

4. 0.005

5. 0.005

1. 3,000,000

2. 3,000,000

3. 3,000,000

4. 2,250,000

5. 750,000

d)

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A

 

 

 

£0.005

e)

Date of Transaction

 

 30 December 2025

f)

Place of transaction

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGCGDBSGGDGLR
Date   Source Headline
19th Nov 20248:00 amRNSShareholder Question & Answers
13th Nov 20247:00 amRNS6,700m Drilling Programme to Commence
12th Nov 20243:11 pmRNSHolding(s) in Company
7th Nov 20247:00 amRNSResults of Retail Offer
6th Nov 20247:01 amRNSBookBuild Retail Offer
6th Nov 20247:00 amRNSCapital Raise of £1.5m
8th Oct 20247:00 amRNSGlobal MSP Accreditation
5th Sep 20247:00 amRNSMoU signed for Graphite Beneficiation in Uganda
2nd Sep 20247:00 amRNS600 tonne Processing Graphite to Battery Ready SPG
22nd Jul 20247:00 amRNSIssue of Equity
15th Jul 20247:00 amRNSDFC Grant Fourth Tranche
5th Jul 20247:00 amRNSConversion of 600t bulk sample to concentrate
25th Jun 20247:17 amRNS600t Bulk Sample Nearing Completion
14th Jun 20247:00 amRNSHalf-year Report
10th Jun 20247:00 amRNSFirst offtake for 15,000 tonnes
3rd Jun 20247:00 amRNSCorporate Presentation Updated
28th May 20249:00 amRNSCEO Video Interview
15th Apr 20247:00 amRNSBulk Sample Update
10th Apr 20247:00 amRNSReceipt of Third Tranche from DFC
26th Feb 20248:52 amRNSResult of AGM
9th Feb 20247:00 amRNSSubscription & Conditional Subscription - Replace
6th Feb 20247:00 amRNSSubscription & Conditional Subscription
31st Jan 20247:00 amRNSAnnual Financial Report
29th Jan 20247:00 amRNSDFC LOI Regarding Project Financing
25th Jan 20247:00 amRNSReceipt of further $1m Tranche from the DFC
2nd Jan 20247:00 amRNSProject Update
11th Dec 20237:00 amRNSDFS Update
30th Oct 20237:00 amRNSSPG Test Work Completed
10th Oct 202312:16 pmRNSReceipt of $1m Grant First Tranche from DFC
22nd Sep 20237:05 amRNSCorporate Presentation
22nd Sep 20237:00 amRNSDFC Grant Completed
4th Sep 20237:00 amRNSBulk Sampling Completed
23rd Aug 20237:16 amRNSHolding(s) in Company
14th Aug 20237:57 amRNSBulk Sampling Update & China Visit
18th Jul 20237:00 amRNSWarrants Update
22nd Jun 20231:49 pmRNSCEO Interview
19th Jun 20237:00 amRNSMetallurgical test work results
2nd Jun 20237:00 amRNSHalf-year Report
24th May 20238:59 amRNSHolding(s) in Company
18th May 20237:46 amRNSPlacing to Raise £635,000
9th May 20237:00 amRNSWebinar Today
2nd May 20237:11 amRNSInvestor Webinar & Updated Presentation
27th Apr 20233:22 pmRNSStrategic Funding Partner for Orom-Cross
18th Apr 20237:00 amRNSWarrant Expiry Extension
2nd Mar 20237:49 amRNSResearch Note
27th Feb 20237:00 amRNSBulk Sampling Complete
15th Feb 202310:17 amRNSResult of AGM
23rd Jan 20237:00 amRNSAppointment of Leading Engineering Firm to DFS
16th Jan 20237:00 amRNSFinal Metallurgical Testing Programs
13th Jan 20237:00 amRNSAnnual Results 30 September 2022 & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.